Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology company whose news flow reflects activity across medical discovery, diagnostics, drug delivery and interventional care. On this page, readers can follow company-issued updates and third-party coverage related to BD’s operations, product clearances, collaborations and corporate developments.
Recent BD news highlights regulatory milestones, such as U.S. FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, a multi-modality breast biopsy platform designed to support early detection and diagnosis of breast disease. Other announcements showcase BD’s role in supporting the pharmaceutical supply chain, including investments to expand production of BD Neopak™ Glass Prefillable Syringes in the United States to help meet growing demand for biologic and GLP-1 drug delivery.
Investors and observers can also track BD’s clinical and surgical innovations, including milestones with Phasix™ Mesh for hernia prevention in Europe and progress in the PREVENT trial, as well as the European launch of the BD Surgiphor™ Surgical Wound Irrigation System. In diagnostics and research, BD reports collaborations with institutions such as the University of Pennsylvania’s Institute for Immunology and Immune Health, and product updates like new IVDR-certified VIASURE assays for the BD MAX™ System and expanded configurations of BD FACSDiscover™ A8 Cell Analyzers.
Corporate governance and financial communications feature in BD’s news as well, with items such as leadership appointments in investor relations and notices regarding annual shareholder meetings. This news feed offers a centralized view of BD’s product pipeline, strategic investments, partnerships and regulatory events, providing context for how the company positions itself within the medical technology landscape.
BD (NYSE: BDX) announced on November 13, 2025 that Duncan Regional Hospital is the first U.S. hospital to go live with BD Alaris™ EMR Infusion Interoperability integrated with MEDITECH. The integration enables bi-directional communication between MEDITECH and Alaris infusion pumps, allowing clinicians to scan to verify patients, medications and pumps; send infusion orders from MEDITECH to pumps; and receive infusion status back into the EHR.
The rollout expands BD's market-leading interoperability—now live at more than 960 U.S. sites—to all three leading U.S. EHRs, and BD reports a pace of about 12 new site activations per month.
BD (NYSE: BDX) on Nov 12, 2025 introduced the PureWick™ Portable Collection System, a battery-powered, non-invasive urine management device designed for wheelchair users and mobile use.
Key facts: the device offers up to 8 hours battery life, is mountable or carriable, compatible with PureWick™ male and female external catheters, and is sold via PureWickAtHome.com and phone ordering. The PureWick portfolio has sold > 55 million external catheters and is used in > 4,500 hospitals and rehab facilities in the U.S.; a survey of 150 users/caregivers found > 90% would recommend the PureWick urine collection system. BD positions the portable unit to improve mobility, discretion, and skin protection for people managing urinary incontinence.
BD (NYSE: BDX) reported fiscal 2025 Q4 revenue of $5.9B (+8.3% reported, +7.0% FXN, +3.9% organic) and fiscal 2025 revenue of $21.8B (+8.2% reported, +7.7% FXN, +2.9% organic).
Q4 GAAP diluted EPS was $1.72 and adjusted diluted EPS was $3.96. Full-year GAAP EPS was $5.82 (down 0.7%) and adjusted diluted EPS was $14.40 (+9.6%). Adjusted operating margin improved to 25.0%; GAAP operating margin was 11.8%.
BD returned $2.2B to shareholders in FY25 and provided FY26 guidance of low single-digit revenue growth and adjusted diluted EPS of $14.75–$15.05. Management reiterated the planned combination of Biosciences and Diagnostic Solutions with Waters around end of Q1 CY2026.
BD (NYSE: BDX) declared a quarterly dividend of $1.05 per share, a 1.0% increase from the prior quarter. The dividend is payable on December 31, 2025 to holders of record on December 8, 2025.
The company set an indicated annual dividend rate for fiscal year 2026 of $4.20 per share. This marks the 54th consecutive fiscal year BD has raised its dividend, maintaining its membership in the S&P 500 Dividend Aristocrats Index. Management linked the increase to confidence in BD's long-term outlook during execution of the Waters RMT transaction.
BD (NYSE: BDX) announced on November 4, 2025 that the AGILITY IDE study has achieved full enrollment of the common and external iliac artery cohort (n=118) for the Revello™ Vascular Covered Stent in peripheral artery disease (PAD).
The multi-center, prospective AGILITY study (NCT06111469) is enrolling at up to 45 sites across the United States, Europe, Australia and New Zealand and includes a second cohort for superficial femoral and proximal popliteal arteries (n=223) with enrollment ongoing. The milestone was announced during a late-breaking presentation at VIVA 2025 by Dr. Sean Lyden.
BD (NYSE: BDX) received FDA 510(k) clearance and CE-IVDR/CE marking for its Enteric Bacterial Panel (EBP) and Enteric Bacterial Panel plus (EBP plus) for the BD COR™ System on Nov 3, 2025.
The molecular panels use PCR on the BD COR system to detect a broad range of GI bacterial pathogens from a single stool swab and run on a high-throughput automated system with capacity for nearly 1,650 tests and up to 1,000 sample results in 24 hours, plus up to 7 hours walk-away time and room-temperature reagents.
BD (NYSE: BDX) announced an IVDR-certified, dry self-collection swab and fully automated lab workflow for HPV testing outside the United States on Oct 22, 2025. The solution enables safe at-home sample collection without liquids, supports mailing to labs, and requires no manual sample preparation for clinical laboratory technologists when used with the BD COR™ System.
Key technical points:
- 30-day dry sample stability, including up to 5 days at 45°C and 4 freeze/thaw cycles
- Onboard Rehydration Technology to eliminate manual prep
- Barcode-driven unified workflow and internal cellular control for specimen integrity
The product is expected to be commercially available across IVDR-recognized markets in the coming months.
BD (NYSE: BDX) on Oct 20, 2025 launched the BD Incada™ Connected Care Platform, an AI-enabled, AWS-based cloud platform that unifies BD device data into a single ecosystem and supports analytics for nearly 3 million smart connected BD devices.
At the same time BD introduced the next-generation BD Pyxis™ Pro Dispensing Solution, a stackable automated medication dispenser that adds capacity (up to 538 multi-access or 98 secure pockets) in a similar footprint, and adds security, RFID badge scanning, wireless barcode scanning and illuminated bins.
The combined offering emphasizes enterprise-wide medication visibility, natural-language analytics, customizable dashboards, and secure cloud storage aimed at reducing medication waste, improving labor efficiency, and speeding point-of-care access. BD notes the Pyxis system processes about 9.8 million transactions per day.
BD (NYSE: BDX) celebrated 65 years of manufacturing at its Broken Bow, Nebraska facility on Oct. 16, 2025. The site opened Oct. 18, 1960 and has grown from a 13,753-square-foot plant with 20 associates to a 310,000-square-foot facility employing nearly 600 associates.
Broken Bow is described as the world's largest manufacturer of BD Vacutainer® tubes, producing billions of tubes and other collection products annually. BD reports more than $50 million invested in Nebraska since 2020 and announced a separate >$35 million investment and 50 jobs at its Columbus facility. BD operates 30+ U.S. sites with ~10,000 employees.
BD (NYSE: BDX) announced a CFO transition: Chris DelOrefice will depart effective Dec. 5, 2025 and Vitor Roque will become interim CFO. The company provided preliminary unaudited results for the period ended Sept. 30, 2025, including Q4 revenue ≈ $5.9 billion (reported +8.3%, currency‑neutral +7.0%, organic +3.9%) and full‑year revenue ≈ $21.8 billion (reported +8.2%, currency‑neutral +7.7%, organic +2.9%).
BD expects fiscal 2025 adjusted diluted EPS to be at or above the midpoint of prior guidance, and will discuss results on an audio webcast Nov. 6, 2025. Preliminary figures are unaudited and subject to change.